ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8358-8377

  Giannini, Giuseppe ^a   Vesci, Loredana ^a   Battistuzzi, Gianfranco ^a   Vignola, Davide ^a   Milazzo, Ferdinando M ^a   Guglielmi, Mario Berardino ^a   Barbarino, Marcella ^a   Santaniello, Mosè ^a   Fantò, Nicola ^a   Mor, Marco ^b   Rivara, Silvia ^b   Pala, Daniele ^b   Taddei, Maurizio ^c   Pisano, Claudio ^a,d   Cabri, Walter ^a,e  

^a Sigma Tau SpA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d Grande Ospedale Metropolitano   (Italy)

^e Fresenius Kabi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CARBOPLATIN; HISTONE DEACETYLASE INHIBITOR; PRODRUG; ROMIDEPSIN; ST 7612AA1; THIOL DERIVATIVE; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; ANILIDE; ANTINEOPLASTIC AGENT; HDAC8 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; REPRESSOR PROTEIN; THIOACETIC ACID S-(6-((5-OXOPYRROLIDINE-2-CARBONYL)AMINO)-6-PHENYLCARBAMOYLHEXYL) ESTER; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CHEMICAL STRUCTURE; CHIRALITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; HUMAN; HUMAN CELL; IC50; LIVER CELL; LUNG CANCER; MOLECULAR DOCKING; MOUSE; NONHUMAN; PHARMACOPHORE; STEREOCHEMISTRY; ANIMAL; CHEMISTRY; DRUG SCREENING; FEMALE; HCT116 CELL LINE; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MICE, NUDE; MOLECULAR DOCKING SIMULATION; PYRROLIDINONES; REPRESSOR PROTEINS; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908388243     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5008209     Document Type: Article

References (59)

1. Allfrey, V. G.; Faulkner, R.; Mirsky, A. E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis Proc. Natl. Acad. Sci. U. S. A. 1964, 51, 786-794
2. Ecker, J.; Witt, O.; Milde, T. Targeting of histone deacetylases in brain tumors Future Med.-CNS Oncol. 2013, 2, 359-376
3. Bantscheff, M.; Hopf, C.; Savitski, M. M.; Dittmann, A.; Grandi, P.; Michon, A. M.; Schlegl, J.; Abraham, Y.; Becher, I.; Bergamini, G.; Boesche, M.; Delling, M.; Dümpelfeld, B.; Eberhard, D.; Huthmacher, C.; Mathieson, T.; Poeckel, D.; Reader, V.; Strunk, K.; Sweetman, G.; Kruse, U.; Neubauer, G.; Ramsden, N. G.; Drewes, G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nature Biotechnol. 2011, 29, 255-265
4. Spiegel, S.; Milstien, S.; Grant, S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy Oncogene 2012, 31, 537-551
5. Giannini, G.; Cabri, W.; Fattorusso, C.; Rodriquez, M. HDAC inhibitors in the treatment of cancer: overview and perspectives Future Med. Chem. 2012, 4, 1439-1460
6. Zhang, L.; Lei, J.; Shan, Y.; Yang, H.; Ma, Y. Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents Mini-Rev. Med. Chem. 2013, 13, 1999-2013
7. Wagner, F. F.; Weïwer, M.; Lewis, M. C.; Holson, E. B. Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases Neurotherapeutics 2013, 10, 589-604
8. Khan, O.; La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications Immunol. Cell Biol. 2012, 90, 85-94
9. Venugopal, B.; Evans, T. R. Developing histone deacetylase inhibitors as anticancer therapeutics Curr. Med. Chem. 2011, 18, 1658-1671
10. Deubzer, H. E.; Schier, M. C.; Oehme, I.; Lodrini, M.; Haendler, B.; Sommer, A.; Witt, O. HDAC11 is a novel drug target in carcinomas Int. J. Cancer 2013, 132, 2200-2208
11. Taunton, J.; Collins, J. L.; Schreiber, S. L. Synthesis of Natural and Modified Trapoxins, Useful Reagents for Exploring Histone Deacetylase Function J. Am. Chem. Soc. 1996, 118, 10412-10422
12. Thaler, F.; Mercurio, C. Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next ChemMedChem 2014, 9, 523-536
13. Valente, S.; Mai, A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011-2013) Expert Opin. Ther. Patents 2014, 24, 1-15
14. Grassadonia, A.; Cioffi, P.; Simiele, F.; Iezzi, L.; Zilli, M.; Natoli, C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Cancers 2013, 5, 919-942
15. Suzuki, T.; Miyata, N. Rational design of non-hydroxamate histone deacetylase inhibitors Mini-Rev. Med. Chem. 2006, 6, 515-526
16. Matheson, A. J.; Noble, S. Racecadotril Drugs 2000, 59, 829-835 (discussion 836-837)
17. Pires de Lima, D. Synthesis of angiotensin-converting enzyme (ACE): an important class of antihypertensive drugs Quím. Nova 1999, 22, 375-381
18. Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates J. Med. Chem. 2005, 48, 1019-1032
19. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 3313-3317
20. Itoh, Y.; Suzuki, T.; Kouketsu, A.; Suzuki, N.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors J. Med. Chem. 2007, 50, 5425-5438
21. Huang, D.; Li, X.; Sun, L.; Xiu, Z.; Nishino, N. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents J. Pept. Sci. 2012, 18, 242-251
22. Breslow, R.; Belvedere, S.; Gershell, L.; Miller, T. A.; Marks, P. A.; Richon, V. M.; Rifkind, R. Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof. U.S. Patent 6,511,990-B1, 2003.
23. Breslow, R.; Marks, P. A.; Abhilash, K. G.; Wang, J. Selective HDAC inhibitors. WO 2011146855, 2011.
24. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401, 188-193
25. Hanessian, S.; Auzzas, L.; Giannini, G.; Marzi, M.; Cabri, W.; Barbarino, M.; Vesci, L.; Pisano, C. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence Bioorg. Med. Chem. Lett. 2007, 17, 6261-6265
26. Hanessian, S.; Auzzas, L.; Larsson, A.; Zhang, J.; Giannini, G.; Gallo, G.; Ciacci, A.; Cabri, W. Vorinostat-Like Molecules as Structural, Stereochemical, and Pharmacological Tools Med. Chem. Lett. 2010, 1, 70-74
27. Auzzas, L.; Larsson, A.; Matera, R.; Baraldi, A.; Deschenes-Simard, B.; Giannini, G.; Cabri, W.; Battistuzzi, G.; Gallo, G.; Ciacci, A.; Vesci, L.; Pisano, C.; Hanessian, S. Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity J. Med. Chem. 2010, 53, 8387-8399
28. Taddei, M.; Cini, E.; Giannotti, L.; Giannini, G.; Battistuzzi, G.; Vignola, D.; Vesci, L.; Cabri, W. Lactam based 7-amino suberoylamidehydroxamic acids as potent HDAC inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 61-64
29. Witt, D.; Klajn, R.; Barski, P.; Grzybowski, B. A. Applications, Properties and Synthesis of ω-Functionalized N -Alkanethiols and Disulfides-The Building Blocks of Self-Assembled Monolayers Curr. Org. Chem. 2004, 8, 1763-1797
30. Watanabe, L. A.; Jose, B.; Kato, T.; Nishino, N.; Yoshida, M. Synthesis of l -α-amino-ω- bromoalkanoic acid for side chain modification Tetrahedron Lett. 2004, 45, 491-494
31. Zhi, J.; Xiao, Y.; Hu, A. Synthesis of thiol-containing amino acids through alkylation of glycinateketimine Synth. Commum. 2012, 42, 914-920
32. Lahm, A.; Paolini, C.; Pallaoro, M.; Nardi, M. C.; Jones, P.; Neddermann, P.; Sambucini, S.; Bottomley, M. J.; Lo Surdo, P.; Carfí, A.; Koch, U.; De Francesco, R.; Steinkühler, C.; Gallinari, P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 17335-17340
33. Yang, X. J.; Gregoire, S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication Mol. Cell. Biol. 2005, 25, 2873-2884
34. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfí, A.; De Francesco, R.; Steinkühler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Rep. 2007, 8, 879-884
35. Oger, F.; Lecorgne, A.; Sala, E.; Nardese, V.; Demay, F.; Chevance, S.; Desravines, D. C.; Aleksandrova, N.; Le Guével, R.; Lorenzi, S.; Beccari, A. R.; Barath, P.; Hart, D. J.; Bondon, A.; Carettoni, D.; Simonneaux, G.; Salbert, G. Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilidehydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring J. Med. Chem. 2010, 53, 1937-1950
36. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B. C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases Structure 2004, 12, 1325-1334
37. Strickley, R. G. Solubilizing excipients in oral and injectable formulations Pharm. Res. 2004, 21, 201-230
38. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New Colorimetric Citotoxycity Assay for Anticancer-drug Screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
39. Maestro, version 9.6; Schrödinger, LLC: New York, 2013.
40. LigPrep, version 2.8; Schrödinger, LLC: New York, 2013.
41. Schrödinger Suite 2013 Protein Preparation Wizard; Schrödinger, LLC: New York, 2013
42. Epik version 2.6; Schrödinger, LLC, New York, NY, 2013
43. Impact, version 6.1; Schrödinger, LLC: New York, 2013
44. Prime, version 3.3; Schrödinger, LLC: New York, 2013.
45. Glide, version 6.1; Schrödinger, LLC: New York, 2013.
46. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
47. Watson, P. J.; Fairall, L.; Santos, G. M.; Schwabe, J. W. R. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate Nature 2012, 481, 335-340
48. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfí, A.; De Francesco, R.; Steinkühler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Rep. 2007, 8, 879-884
49. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236
50. Cole, K. E.; Dowling, D. P.; Boone, M. A.; Phillips, A. J.; Christianson, D. W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases J. Am. Chem. Soc. 2011, 133, 12474-12477
51. MacroModel, version 10.2; Schrödinger, LLC: New York, 2013.
52. Dowling, D. P.; Gantt, S. L.; Gattis, S. G.; Fierke, C. A.; Christianson, D. W. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors Biochemistry 2008, 47, 13554-13563
53. Desmond Molecular Dynamics System, version 3.6, D. E. Shaw Research: New York, 2013
54. Maestro-Desmond Interoperability Tools, version 3.6; Schrödinger: New York, 2013.
55. Bowers, K. J.; Chow, E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregerson, B. A.; Klepeis, J. J.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, G. D.; Salmon, J. K.; Shan, Y.; Shaw, D. E. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters, Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa, FL; Institute of Electrical and Electronics Engineers (IEEE): New York, 2006.
56. Feller, S. E.; Zhang, Y.; Pastor, R. W.; Brooks, B. R. Constant pressure molecular dynamics simulation: the Langevin piston method J. Chem. Phys. 1995, 103, 4613-4621
57. Lippert, R. A.; Bowers, K. J.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Shaw, D. E. A common, avoidable source of error in molecular dynamics integrators J. Chem. Phys. 2007, 126, 046101
58. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A smooth particle mesh ewald method J. Chem. Phys. 1995, 103, 8577-8593
59. Tuckerman, M.; Berne, B. J.; Martyna, G. J. Reversible multiple time scale molecular dynamics J. Chem. Phys. 1992, 97, 1990-2001.